Editor’s note: This is a developing news story. Please check back soon for updates.
The FDA approved Eydenzelt, a biosimilar referencing Eylea, for the treatment of four retinal diseases, according to a press release from Celltrion.
These conditions include wet age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy.
According to the release, the FDA based its decision on Eydenzelt (aflibercept-boav) on analytical, nonclinical and clinical data. Notably, a randomized, double-masked, parallel-group, multicenter, 52-week